IL6 and COVID-19: In COVID-19 patients, overproduction of cytokines, such as IL-6, might activate coagulation pathways, with a resultant disruption of procoagulant–anticoagulant homeostasis, induction of disseminated intravascular coagulation, and multiorgan dysfunction or failure (Jose and Manuel, 2020).